bisantrene + decitabine + cedazuridine

**bisantrene + decitabine + cedazuridine** is an investigational combination therapy studied primarily in hematologic malignancies. **Bisantrene** is an anthracene-based chemotherapeutic agent with intercalating and topoisomerase II inhibitory properties, showing antineoplastic activity through inhibition of DNA and RNA synthesis, DNA intercalation, and topoisomerase II inhibition. **Decitabine** is a DNA methyltransferase inhibitor (hypomethylating agent) that induces DNA hypomethylation and cell differentiation/apoptosis. **Cedazuridine** is a cytidine deaminase inhibitor that increases oral bioavailability of decitabine by inhibiting its metabolism. The fixed-dose oral combination of decitabine and cedazuridine (commercialized as Inqovi) is FDA-approved for myelodysplastic syndromes. The triple combination (bisantrene + decitabine + cedazuridine) is under clinical investigation for acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML) in patients with extramedullary disease, particularly those unable or unwilling to undergo intensive chemotherapy.

Other names

bisantrene + decitabine/cedazuridinebisantrene + ASTX727